Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 6/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605559 | 1.00 | SQOR (0.53) | SQORERN1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL31432885 | 0.90 | ERN1 (0.53) | SQORERN1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL28136895 | 0.85 | SQOR (0.49) | SQORALDH1A1MAPTGRM5SMN1; SMN2 | |
| SCHEMBL12274337 | 0.84 | SQOR (0.48) | SQORALDH1A1MAPTGRM5SMN1; SMN2 | |
| SCHEMBL28074923 | 0.84 | SQOR (0.48) | SQORALDH1A1MAPTGRM5SMN1; SMN2 | |
| SCHEMBL244521 | 0.84 | SQOR (0.48) | SQORALDH1A1MAPTGRM5SMN1; SMN2 | |
| SCHEMBL5752318 | 0.80 | SQOR (0.49) | SQORADORA2AADORA1ALDH1A1NPC1 | |
| SCHEMBL15709345 | 0.80 | ADORA2A (0.47) | SQORADORA2AADORA1ALDH1A1 | |
| SCHEMBL1318923 | 0.78 | ADORA2A (0.44) | ADORA2AADORA1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL9815139 | 0.77 | ALDH1A1 (0.58) | SQORERN1ALDH1A1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| EP-3810602-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334466-A | Compound (I) | CTXT私人有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | SQOR 1053/4885ERN1 2074/4885ADORA2A 4338/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | SQOR 1053/4885ERN1 2075/4885ADORA2A 4335/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | SQOR 4561/4885ERN1 3732/4885ADORA2A 2191/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | SQOR 1053/4885ERN1 2075/4885ADORA2A 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.